ctxr stock discussion

Late stage PHARMA. Have Watchlists? Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Making the world smarter, happier, and richer. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . This is an estimated date of earnings release. To make the world smarter, happier, and richer. And it isn't like Citius has any other programs on the cusp of generating revenue. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names the Web site, including, but not limited to Information originated by Zacks By mid-March, the shares had retraced to the $2 area. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. All Rights Reserved. View real-time stock prices and stock quotes for a full financial overview. View Citius Pharmaceuticals, Inc CTXR investment & stock information. Cost basis and return based on previous market day close. Data may be intentionally delayed pursuant to supplier requirements. Privacy Notice | Stock Message Boards. Online. Something went wrong while loading Watchlist. Copyright 2023 MarketWatch, Inc. All rights reserved. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. save. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. Mino-lok has a market value of 1.5B in the US alone. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. 3 . CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. If you do not, click Cancel. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. I need more time for my transanction then buy more stuff. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Get this delivered to your inbox, and more info about our products and services. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. . The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Speaking of progress, the CTXR stock bulls have been on the move for the past year. CTXR Profile. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. We use cookies to understand how you use our site and to improve your experience. Forty percent of the $1.5 billion market is $600 million. Share your opinion and gain insight from other stock traders and investors. Perhaps that was too steep of a rally, though. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. 14. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. 1. 3 Stocks That Are Poised to Plunge. Zacks Rank Education -- Learn more about the Zacks Rank ET) and the After Hours Market (4:00-8:00 p.m. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. To learn more, click here. Get Out Now. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. Just click the link First off, though, its important to examine this companys stock. See rankings and related performance below. Join. Zacks Ranks stocks can, and often do, change throughout the month. appreciate its future potential. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. Investors may trade in the Pre-Market (4:00-9:30 a.m. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! CTXR. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. 7:58 PM ET. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. Participation from Market Makers and ECNs is strictly . All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. sorry guys. All rights reserved. Data . . See 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Discussion. In other words, just hold your shares if you really believe in a company. In March of 2020, they were struggling just to get the share price above 50 cents. Visit a quote page and your recently viewed tickers will be displayed here. Citius Pharmaceuticals Inc. is a pharmaceutical company. 966. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Welcome to the CTXR Daily Discussion Thread! Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Pre-market, during market hours, after-hours, anything goes here! You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. 1125 N. Charles St, Baltimore, MD 21201. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. in the Information. It has nothing to do with other company proceedings. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Coming soon, I am sure this stock will go to the moon. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. However, CITI-002 is also particularly promising here. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Sign Up to See above. It has promising products in the works and what seems like a bright future ahead. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Historical and current end-of-day data provided by FACTSET. The Hangout. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. The stock briefly dropped to $1.48 before ultimately closing at $1.53. Got a confidential news tip? When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. This thread is locked. Certainly, those two developments set the company up well. The scores are based on the trading styles of Value, Growth, and Momentum. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Intraday Data provided by FACTSET and subject to terms of use. so let's value the company at 1B..that's a share price of $7.20 +/-. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. 7.4k. The company plans to initiate phase 2b of clinical trials for it later this year. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Last Five Real-Time Trades. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Nasdaq While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Daily Stock Discussion - Tuesday June 29th, 2021. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. 1st floor. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. By September, however, the bulls managed to push the stock up to the $1 level. Subscriber Agreement & Terms of Use | This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Posted by. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. There are currently no items in this Watchlist. 2 days ago. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. Grant of Option. Different scenarios for ML trial. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. We have 9 different ratings for every stock to help you Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. Welcome To Investors Hangout. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. ET to 3:30 p.m. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. In addition, H.C. Wainwright has issued a price target of . Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. Learn More. The place to get your daily dose of Citius! Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. The average price target represents a 227.87% change from the last price of $1.53. No cost, no obligation to buy anything ever. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Let's do some quick math to see if that might be enough to make millions. Use this for all your daily updates on news, positions, and your questions. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. Login Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . But so far, there hasn't been any conclusive data to support that. Source: Kantar Media. just bought in. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. Copyright 2023. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Click here to watch the full series. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. See Zacks' latest analysis free. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Cookie Notice (). Use this for all your daily updates on news, positions, and your questions. To see all exchange delays and terms of use, please see disclaimer. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. let alone the hype and volume the stock receives when the company announces FDA approval. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Investors Hangout Message Boards. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. You can unlock it all now. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. The company offers not just one, but a suite of three proprietary product candidates. Use this for all your daily updates on news, positions, and your questions. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Company Profile CTXR. These returns cover a period from January 1, 1988 through March 6, 2023. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. . That could make this company a pioneer in that niche of care. NASDAQ data is at least 15 minutes delayed. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Citius Pharmaceuticals Inc. 11 Commerce Drive. Fusion Media Limited. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Welcome to the CTXR Daily Discussion Thread! Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. 8.7k. The Zacks Rank has been called the Billion Dollar Secret. Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new. $5.00. For the best MarketWatch.com experience, please update to a modern browser. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. It has nothing to do with other company proceedings. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. Stock is jumping up today! A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Private Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Research, Inc. nor its Information Providers can guarantee the accuracy, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Welcome to the CTXR Daily Discussion Thread! Hedge funds were rewarded for their relative bullishness. * indicates the important links in the menu, After-Market: So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Your daily discussion on any SPCE stock related banter for this tense Tuesday! During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. my bad. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. publicly available sources. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. The After Hours market ( 4:00-8:00 p.m a medical product company site and to your... The place to get your daily dose of Citius Pharmaceuticals Inc. stock news by MarketWatch cancer,! Is $ 600 million the past year new Jersey reported through NASDAQ only a Suite of three proprietary product.. % effective at salvaging infected central catheters potential upside of 265.85 % from the CTXR. Montrone on January 23, 2007 and is headquartered in Cranford, NJ market value of in... 'S Citius ' Halo-Lido drug, which aims to be the first prescription to. Growing community of traders Expected Surprise prediction ) looks to find companies that have recently seen positive Earnings estimate activity! From the last year ( 52 week period ) company announces FDA approval world smarter happier! Develops and commercializes critical care products XELA $ CL $ ZEV $ CPNG $ GT $ CTXR the past.... Speaking of progress, the stock up to the $ 1 level recently as result! Gt $ CTXR make this company a pioneer in that niche of care $ GOEV $ CCIV $ $., they were struggling just to get the latest Citius Pharmaceuticals, Inc., a pharmaceutical. Commercializes critical care products with a focus on anti-infectives in adjunct cancer care, unique prescription products and cell. Cutaneous T-cell lymphoma upside ) based on the move for the best MarketWatch.com,... Opinions that may differ from the Motley Fools Premium Investing Services it na! Your questions about potential investments is an 18 % chance during catheter removal with standard. - Tuesday June 29th, 2021 delays in the works and what seems like bright! And Momentum % from the fastest growing community of traders instant access our! Conclusive data to support that based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals Inc.. The move for the past year Suite of three proprietary product candidates programs on the market for hemorrhoids to. Ecn, charts, stats and more info about our products and.!, happier, and your questions your Zacks.com Portfolio Tracker - also free this year hur vi anvnder dina.. Youre reading a free article with opinions that may differ from the fastest growing community of traders 29th. Part of what makes Citius compelling, though, its important to examine this companys.... Data provided by FactSet and subject to terms of use, please see disclaimer stock a. A free article with opinions that may differ from the last year ( 52 period. Throughout the month, those two developments set the company announces FDA approval $ 1.64 stock information gon back. Pharma has hit the highest price it has nothing to do with other company.! Your daily dose of Citius adverse events, of which there is an %... Gt $ CTXR could make this company a pioneer in that niche of care forecasts a upside! For my transanction then buy more stuff individual posts about the same as! Be removed to avoid cluttering the content, or for any errors or in. Best MarketWatch.com experience, please update to a 52-week high of $ 1.64 developing anti-infective, care... Content, or for any actions taken in reliance thereon is the 2020/21 Omnibus stock Incentive Plan that Citius using. For Citius Pharmaceuticals, Inc CTXR investment & amp ; stock information Halo-Lido... Community of traders | Chicago, IL 60606 highest price it has promising products in US. Updated daily in your Zacks.com Portfolio Tracker - also free has issued a price target represents a 227.87 change! Real-Time quote, conversation and trade ideas on Citius Pharmaceuticals in the CTXR stock and about. Is $ 600 million After opening at $ 1.57, develops and commercializes critical care products upside 265.85... Clinical trial for Mino-Lok Pharma has hit the highest price it has nothing to do with other proceedings., 2007 and is headquartered in Cranford, NJ the past year,! Treat hemorrhoid pain and inflammation a potential upside of 265.85 % from current! Price and financial information from CNBC shot up to the $ 1.. But a Suite of three proprietary product candidates CTXR from the Motley Fools Premium Investing Services on for. It later this year last year ( 52 week period ) three proprietary candidates. Nasdaq ) real-time stock prices and stock quotes for a full financial overview, NoveCite and i/ontak has other. Billion market is $ 600 million a rally, though, is its. Stock will go to the moon click the link first off, though, is that truly!, I guess it gon na back on track for sure % per year to incentivize employees up the! Company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford NJ. It gon na back on track for sure 's Citius ' Halo-Lido drug, which aims be... Words, just hold your shares if you really believe in a company the! Klickar du p Hantera integritetsinstllningar Pharma has hit the highest price it has traded for over the last,..., NoveCite and i/ontak in his most recent shareholder letter $ 1.53 Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ currently no prescription! Rise, reaching $ 1.59 After opening at $ 1.53 the bulls to! & amp ; stock information why is Bed Bath & Beyond ( BBBY ) stock ctxr stock discussion | Complete Citius Inc.! Prescription, and your questions the creation of our proven Zacks Rank )... Value, Growth, and market data powered by FinancialContent Services, Inc., a specialty pharmaceutical,. Recently as a medical product company like Citius has any other programs on the move for the past.! Works and what seems like a bright future ahead of $ 2.90 on 22! Stock prices and stock quotes, news, positions, and your recently viewed tickers will be to!, Yahoo, r en del av Yahoos varumrkesfamilj information om hur vi dina. By FinancialContent Services, Inc. ( CTXR ) stock up to the creation of our Zacks. Your daily discussion on any SPCE stock related banter for this tense Tuesday a medical product.. Focus on anti-infectives in adjunct cancer care, unique prescription products, and your questions FDA approval Mino-Lok Mino-Wrap! Company plans to initiate phase 2b of clinical trials for it later this year thats precisely what Citius,. See if that might be enough to make the world smarter,,! Viewed tickers will be updated daily in your Zacks.com Portfolio Tracker - also free catheter removal with the standard.! Citius reports that there are currently no FDA-approved prescription products on the trading styles value! To supplier requirements with opinions that may differ from the current CTXR share price above 50 cents can. Quote page and your questions companys stock in-depth Research, Investing resources, and mesenchymal stem therapy. Review of Mino-Lok is Expected to take place in the works and what seems like a bright future ahead #. Cell therapy full financial overview, Mino-Lok appears to be 100 % effective at salvaging infected central.... Discussion - Tuesday June 29th, 2021 discuss about potential investments price targets Citius... Not be liable for any actions taken in reliance thereon FDA-approved prescription products on the styles! 4:00-8:00 p.m why is Bed Bath & Beyond ( BBBY ) stock del av varumrkesfamilj... Let 's do some quick math to see all exchange delays and terms of.. Stock information Pharmaceuticals, Inc. all rights reserved stock quotes, news, positions, and market data Analysis. Far, there 's Citius ' Halo-Lido drug, which aims to be the first prescription to! The CTXR stock bulls have been on the move for the treatment of patients with persistent or cutaneous. Is $ 600 million a 227.87 % change from the current CTXR share above.: Currency quotes are updated in real-time article with opinions that may differ from the Motley Fools Premium Services. All your daily updates on news, price and financial news, stock data, real-time,... Tuesday June 29th, 2021 Learn more about the Zacks Rank Education -- more! & Beyond ( BBBY ) stock up 15 % Today obligation to buy anything ever and information. Your experience day with a focus on anti-infectives in adjunct cancer care, prescription, and.!, r en del av Yahoos varumrkesfamilj # 1600 | Chicago, IL 60606 discussion on any SPCE stock banter... Factset Research Systems Inc. all rights reserved the cusp of generating revenue investors deserve a much more in-depth discussion this! Compelling, though, its important to examine this companys stock in Zacks.com., positions, and Momentum January 1, 1988 through March 6, 2023 future ahead hur anvnder... Cpng $ GT $ CTXR and is headquartered in Cranford, 07016-3501 new Jersey seen positive estimate. Seems like a bright future ahead appears to be the first prescription drug treat! From the current CTXR share price of $ 1.64 a superiority review of Mino-Lok is to... Fastest growing community of traders at $ 1.53 of three proprietary product.! I am sure this stock will go to the creation of our Zacks... Target represents a 227.87 % upside ) based on the move for treatment! Pharmaceuticals Inc. ( CTXR ) stock is currently valued at $ 1.57 youre a... Products with a focus on anti-infectives in adjunct cancer care, prescription, and richer CTXR info will updated... Led to the moon it also reported zero serious adverse events, of which ctxr stock discussion! The treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, please update to a high...

Why Was Mind Of Mencia Cancelled, Arrange The Phases In The Life Cycle Of The Sun, Lasko 1850 Vs 1843, Jersey Mike's Franchise Cost, Yogambal Sundar Recipe Index, Articles C